Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Immunotherapy. 2020 Apr;12(5):269-273. doi: 10.2217/imt-2020-0067. Epub 2020 Mar 26.
No abstract available

Keywords: anti-CTLA-4; COVID-19; SARS-CoV-2; anti-PD-1; anti-PD-L1; cancer patients; immune checkpoint inhibitors; immunotherapy; tocilizumab; viral infection.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections* / etiology
  • Coronavirus Infections* / immunology
  • Coronavirus Infections* / physiopathology
  • Cytokine Release Syndrome
  • Disease Progression
  • Humans
  • Immunotherapy / adverse effects*
  • Neoplasms* / complications
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Pandemics*
  • Pneumonia, Viral* / etiology
  • Pneumonia, Viral* / immunology
  • Pneumonia, Viral* / physiopathology
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • tocilizumab